[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glucose-metabolism-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glucose-metabolism-disorder":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100652310","bao-yuan-tang-extract-and-galactooligosaccharides-for-sleep-regulation-100652310",false,"NCT07774897","Bao Yuan Tang Extract and Galactooligosaccharides for Sleep Regulation","Sleep-Promoting Effects of Bao Yuan Tang Whole-Component Extract Combined With Galactooligosaccharides: A Prospective, Multicenter, Triple-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Female registered nurses aged 25-45 years.\n* Participants must meet at least one of the following criteria, self-reported presence of at least one target symptom of the trial, including insomnia, daytime fatigue, or difficulty initiating sleep or Pittsburgh Sleep Quality Index (PSQI) score \\>7.\n* Engagement in shift work for at least one month before enrollment, with either ≥ 4 night shifts or ≥32 hours of night-shift work during the preceding month.\n\nExclusion Criteria:\n\n* Diagnosed with type 1 or type 2 diabetes mellitus and currently receiving pharmacological treatment.\n* Diagnosed with clinically thyroid dysfunction, including hyperthyroidism or hypothyroidism, and currently receiving pharmacological treatment.\n* Diagnosed with Cushing's syndrome, pituitary dysfunction, or other clearly defined endocrine disorders.\n* Diagnosed with polycystic ovary syndrome (PCOS) and currently receiving pharmacological treatment.\n* Use of medications that may affect study outcomes, including oral contraceptives, glucose-lowering agents, hormonal medications, hypnotics, lipid-regulating agents, or thyroid hormone preparations, within the past 3 months.\n* Pregnancy, lactation, or planned pregnancy during the study period.\n* Confirmed severe organic diseases, such as hepatic or renal insufficiency, cardiovascular disease, or malignancy.\n* Known allergy to any component of the investigational product.\n* Use of probiotics, prebiotics, or related traditional Chinese medicine preparations within the past 1 month.\n* Participation in another clinical trial within the past 3 months.\n* Planned engagement in vigorous exercise or a weight-management program during the study period.\n* A previous diagnosis of psychiatric disorders, such as anxiety or depression.\n* Any condition judged by the investigator to involve communication difficulties, poor compliance, or potential interference with adherence to the study protocol.",true,"FEMALE","25 Years","45 Years",{"count":21,"type":22},400,"ESTIMATED","INTERVENTIONAL",[25],"NA","Certain classical formulas in traditional Chinese medicine and dietary prebiotics have demonstrated beneficial effects on various aspects of suboptimal health status in previous studies. This research aims to evaluate the effects of Bao Yuan Tang full-component extract combined with galactooligosaccharides on improving health-related outcomes in female registered nurse with suboptimal health status, including sleep disturbances, fatigue, endocrine dysregulation, and glucose and lipid metabolic abnormalities.",[28,29,30,31,32],"Sleep Disturbance","Fatigue Syndrome, Chronic","Endocrine Disorder","Glucose Metabolism Disorder","Lipid Metabolism Disorders",[34,35,36,37,38],"Bao Yuan Tang full-component extract","Galactooligosaccharides","Sleep quality","Prebiotic","Metabolic health","NOT_YET_RECRUITING","2026-08-16",{"date":42,"type":43},"2026-08-19","ACTUAL",{"date":45,"type":22},"2026-09-30",{"date":47,"type":22},"2027-09-30",{"name":49,"class":50},"Hepatopancreatobiliary Surgery Institute of Gansu Province","OTHER",6,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":65,"conditions":66,"keywords":72,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100582190","phase-1-impact-of-chromium-supplementation-on-glucido-lipidic-metabolism-oxidative-stress-and-inflammatory-state-in-patients-with-gestational-diabetes-100582190","NCT06860087","Impact of Chromium Supplementation on Glucido-lipidic Metabolism, Oxidative Stress and Inflammatory State in Patients with Gestational Diabetes","Impact of Chromium Supplementation on Glucido-lipidic Metabolism, Oxidative Stress and Inflammatory State in Pregnant Women with Gestational Diabetes Mellitus","Cr and GDM","Inclusion Criteria:\n\n* Healthy pregnant women:\n\n  * Whose their gestational age is 28 weeks\n  * They have no pathology or complication associated with their pregnancy.\n* Pregnant women with gestational diabetes mellitus:\n\n  * They will be selected according to the criteria of the one-step method for screening for gestational diabetes mellitus established by the WHO.\n  * They have no other pathology or complication associated with pregnancy.\n  * They are subjected to insulin therapy and a low-calorie diet, rich in protein, fiber and beneficial lipids (they will all asked to keep their medical treatment prescribed by their doctor).\n* All women involved in this study will be systematically supplemented with 60 mg\u002Fd iron and 400 mg\u002Fd vitamin B9 during pregnancy as recommended by WHO.\n\nExclusion Criteria:\n\n* Pregnant women with unrecognized diabetes, type I or type II, will not be involved in this study.\n* Pregnant women who were supplemented before one month or during pregnancy, or who will need other micronutrient supplements during the study to avoid their influence on the results.\n* Pregnant women who develop other health complications will be removed from the study and replaced by others.\n* Women with gestational diabetes mellitus who were unable to complete chromium supplementation up to 6 weeks will be excluded from the study and replaced by others.",{"count":61,"type":22},200,[63,64],"PHASE1","PHASE2","Our study aims to explore the influence of dietary chromium supplementation in the form of chromium picolinate, at different doses (200 µg and 400 µg per day), on the health of pregnant women with gestational diabetes. This study will also provide more information on the safety of this type of supplementation during pregnancies complicated by gestational diabetes mellitus.\n\nThe main questions it aims to answer are:\n\n* Does chromium supplementation at various doses in women with gestational diabetes mellitus truly influence their glucido-lipidic metabolism, oxidative\u002Fantioxidant balance, and inflammatory state? If so, is it beneficial or detrimental?\n* If this supplementation is beneficial, which dose is the most appropriate?\n* Do these types of supplementation have any side effects on the health of the mother and fetus? The participants will take chromium supplements for 6 weeks (supplemented groups) while the control participants will not take them (healthy and diabetic control groups).\n\nChromium-supplemented participants will undergo a medical check-up every 02 weeks to closely monitor their health status and detect any potential side effects at an early stage.\n\nResearchers will compare the biochemical profile, oxidative stress status, and inflammation markers between chromium-supplemented and non-supplemented participants to assess the impact of this trace element.\n\nResearchers will compare the effects of chromium supplements at different doses with each other.",[67,68,69,70,71,31,32],"Gestational Diabetes Mellitus (GDM)","Oxidative Stress","Inflammatory Status","Insulin Resistance","Leptin Resistance",[73,74,75,76,77,78,79,80],"Inflammatory status markers","Oxidative stress markers","Glucido-lipidic metabolism","HOMA-IR","Leptin level","Lipid profile","Fasting plasma glucose","Insulin level","2025-03-01",{"date":83,"type":43},"2025-03-05",{"date":85,"type":22},"2025-05",{"date":87,"type":22},"2026-01",{"name":89,"class":50},"University of Kasdi Merbah",1]